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1. Introduction 
1.1 Cartilage injuries, the triad and quartet of tissue engineering 
Presently, focal cartilage injuries in humans are treated by abrasion arthroplasty with or 
without subchondral bone microfracture, autologous chondrocyte or mesenchymal stem 
cells (MSC) implantation and osteochondral plugs used in a sequential fashion pending 
severity and duration of the problem (Figure 1) (Williams et al., 2010; Steinert et al., 2007). 
Current strategies in human medicine for treatment of diffuse joint degeneration rely on 
replacement of the whole degenerated joint with inert implants. Excellent treatment 
outcome has been achieved for up to 15 years or more, but approximately 20% of treated 
patients require revision procedures after this time (Steadman et al., 2001). For younger 
patients this current state-of-the-art may translate to two or more revision surgeries during 
their lifetime. A biological solution to repair damaged cartilage that would provide life-long 
pain relief would be a major medical achievement.  
The tissue engineering triad refers to the use of cells, scaffolds and cytokines to engineer 
tissues in vitro or in vivo. Such engineered tissues can potentially be utilized for tissue 
replacement strategies, for pharmacological screening of agents for therapeutic or toxic 
effects, or to gain insight into tissue developmental processes. Cartilage tissue, engineered 
using this triad of components often exhibit hyaline cartilage morphology, but the tissue has 
inferior mechanical properties when compared to native joint cartilage (Grad et al., 2011; 
Schulz and Bader, 2007). A fourth component of tissue engineering, namely mechanical 
stimulation has been added to the classical triad in order to better replicate the in vivo 
environment of joint cartilage (Grad et al., 2011; Schulz and Bader, 2007). Using this 
“quartet” of tissue engineering (cells, scaffolds, cytokines, and mechanical stimuli), cartilage 
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with better mechanical properties has been produced. The mechanical properties of cartilage 
produced using mechanical stimulation may or may not be better than static culture 
depending on the cell source, timing of mechanical stimulation, method and duration of 
mechanical stimulation, and other variables. It is clear that each component of this tissue 
engineering “quartet” should be studied in detail since different cells respond differently to 
different cytokines, scaffold composition and topography as well as mode and timing of 
mechanical stimuli. This underlines the complexity of tissue engineering where each of 
these areas is a separate research field.  
Here, we will briefly discuss the cells used for cartilage tissue engineering followed by more 
detailed discussion of selected topics on scaffolds, cytokines and means of mechanical 
stimuli. Pre-clinical animal models of cartilage repair and future perspectives follow these 
tissue-engineering considerations.  
 
 
Fig. 1. Current articular cartilage treatment algorithm. ACI = autologous chondrocyte 
implantation, MACI = matrix-assisted autologous chondrocyte implantation, TJR = total joint 
replacement. Reprinted with permission from Williams et al. (2010)  
2. Cells of cartilage tissue engineering 
Articular hyaline cartilage is a very specialized tissue characterized by low cellularity, 
extensive extracellular matrix, lack of vascular, lymphatic, and nervous supply, and 
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insufficient number of resident progenitor cells needed for mounting an appropriate 
regenerative response to injury. The result is minimal intrinsic repair capacity.  
The obvious choice of cell for cartilage repair is the chondrocyte from hyaline cartilage since 
it is normally responsible for the production and maintenance of joint cartilage. However, a 
number of factors have limited the use or therapeutic success of chondrocytes. 
Chondrocytes only constitute about 5% of joint cartilage and insufficient chondrocyte 
numbers are therefore often retrieved for immediate therapeutic use, which in turn 
necessitate ex vivo cell expansion prior to re-implantation. Chondrocytes unfortunately tend 
to dedifferentiation towards the fibroblast cell lineage when expanded in culture making 
them less suitable for transplantation (Schulze-Tanzil, 2009). Another limitation to the use of 
autologous chondrocytes is the need for two surgical procedures, weeks apart to harvest 
and later implant the cells, which adds time, cost, anesthetic risk and risks of donor site 
morbidity (Schulze-Tanzil, 2009; Williams et al., 2010). Interestingly, osteoarthritic 
chondrocytes seem to perform equally well in vitro when compared to chondrocytes from 
healthy joints (Dehne et al., 2009; Stoop et al., 2007).  
Stem cells or cells with chondrogenic potential from various tissue sources have been 
investigated for cartilage repair. Adult cells such as bone marrow multipotent stromal cells  
(BM-MSCs) are attractive due to the decreased cost and risks associated with collection 
compared to autologous chondrocytes. Concerns raised with the use of BM-MSCs include 
potentially a decreased yield and differentiation potential of MSCs from the bone marrow 
with increasing age making the technique age-dependent. This is paradoxical to the fact that 
clinical cases often occur in aged individuals (Wilson et al., 2010; Kasper et al., 2009). Adult 
cells with chondrogenic potential have been isolated from a large number of tissues and 
have been reviewed elsewhere (Solchaga et al., 2011; Hildner et al., 2011; O'Sullivan et al., 
2011). Embryonic and recently, induced pluripotent stem cells (iPS cells), may also be 
valuable cell sources for cartilage repair (Hiramatsu et al., 2011; Medvedev et al., 2010; 
Waese and Stanford, 2011; Fecek et al., 2008). Neonatal stem cells with chondrogenic 
potential have been isolated from fresh umbilical cord blood of humans as well as horses 
(Berg et al., 2009; Koch et al., 2007; Santourlidis et al., 2011; Zhang et al., 2011). Human cord 
blood derived stem cells have showed increased proliferation capacity and broader 
differentiation potential compared to stem cells from bone marrow and adipose tissue 
(Zhang et al., 2011; Kogler et al., 2004). Also, cord blood MSCs may be more chondrogenic 
than bone marrow MSCs (Berg et al., 2009; Zhang et al., 2011). 
So far a reliable cell source and method of isolating cells with high chondrogenic potential 
has not been reported. From a tissue-engineering point of view this is a major limitation at 
the moment, since it precludes development of predictable and reproducible protocols for 
cartilage production.  
3. Biomaterials & scaffold fabrication technologies 
Joint cartilage regeneration can be achieved by two strategies, namely cell- and scaffold-
based therapies. Cell therapy has already reached the clinics in the form of autologous 
chondrocyte implantation (ACI) or matrix-assisted ACI (MACI). However, this regenerating 
technique appears to assist only partially in the repair process as it leads to the formation of 
mechanically inferior fibrocartilage compared to native joint cartilage. Although clinical 
outcome is better five years after surgery when compared to the baseline, recent 
comparative studies showed that ACI and MACI were not significantly better than marrow-
stimulating techniques (e.g. microfractures) or reconstructive techniques (e.g. 
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mosaicarthroplasty) using autografts, allografts or synthetic material (Ebert et al., 2011; 
Vasiliadis et al., 2010). The influence of scaffold composition and surface topography on cell 
function and differentiation is being increasingly recognized (Rosso et al., 2005; Milner and 
Siedlecki, 2007; Thakar et al., 2008; Patel et al., 2010). Improvement to the MACI technique 
and other scaffold-based approaches may therefore be made through precise engineering of 
three-dimensional (3D) porous biomaterials – 3D scaffolds – that promote cell lodging, 
migration, and differentiation while providing mechanical support during tissue repair.  
Different biomaterials are used to fabricate scaffolds, predominantly natural and synthetic 
polymers. In general two classes of polymers can be distinguished: (i) hydrogels formulated 
as cell carriers for minimally invasive surgeries; (ii) solid polymers designed for optimal 
mechanical stability. Hereafter, these biomaterials, their physicochemical and mechanical 
properties, and the correspondent fabrication technologies implemented to make 3D 
scaffolds will be discussed. 
3.1 Hydrogels  
A number of general properties should be possessed by hydrogels. Obviously, these 
materials need to elicit an appropriate host response and display satisfactory 
biocompatibility. If a specific hydrogel composition would be associated with prolonged 
inflammation, the resulting immune response toward the encapsulated cells might affect the 
success of the implantation. The gelation mechanism is also important. Typically hydrogels 
are formed by ionic or covalent cross-linking. Ionic cross-links are very dynamic and may be 
formed and disrupted in presence of a multivalent ionic fluid environment, which is like 
physiological fluids. This may hamper the control over the degradation properties of the 
resulting hydrogels. Conversely, covalent cross-links are more stable and confer enhanced 
mechanical and physical properties to the hydrogels. Yet, they are often more toxic and 
more difficult to break than ionic cross-links. This implies that the cross-linking yield should 
always be maximum and different routes for hydrogel degradation should be envisioned in 
the design of covalent cross-linking biodegradable hydrogels (Lee and Mooney, 2001). 
Alternative methods to form cross-links have been developed by exploiting the phase 
transition characteristics of polymers. Temperature sensitive hydrogels have been 
synthesized for tissue engineering applications. These polymers are subjected to a solid to 
gel phase transition at a specific temperature, called lower critical solution temperature, 
which can be tailored to be at body temperature (Fedorovich et al., 2009; Vihola et al., 
2005). Alternatively, stereocomplexation of amphiphilic polymers has also been used as a 
strategy to form physical cross-linked hydrogels. These hydrogels display customized 
physical and mechanical properties depending on the polymer molecular weight and 
relative concentration of the amphiphilic blocks (Hiemstra et al., 2005; Hiemstra et al., 
2006b). Finally, mechanical and degradation properties are important to consider when 
choosing a hydrogel for a specific tissue. Ideally, a hydrogel should possess a similar 
stiffness to that of the targeted tissue and a degradation rate matching the speed of tissue 
formation. 
Natural hydrogels. Among natural hydrogels, alginate, chitosan, hyaluronic acid and its 
derivatives, and collagen have been widely investigated for cartilage repair. Alginate is 
derived from brown algae and is composed of linear block copolymers of mannuronic (M) 
and guluronic (G) acids. It has been widely used in drug delivery and tissue engineering 
applications because of its biocompatibility, relative low cost, abundance, and easy gelation 
in presence of divalent cations (Shapiro and Cohen, 1997; Terada et al., 2005). Ionic cross-
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links are very dynamic and can lead to unpredictable and uncontrollable dissolution of the 
gel in a physiological environment. Therefore covalent cross-links were introduced and 
were shown to improve the mechanical properties and the control over the degradation rate 
of these hydrogels. Alginate is a rather inert biomaterial. In order to enhance cell-material 
interactions, alginate hydrogels have been modified with different biological factors to 
promote cell adhesion or differentiation into specific tissue phenotypes (Hao et al., 2007; 
Hsiong et al., 2008). An important issue is that alginate degradation products often are 
larger than the threshold size for renal clearance. Although previous approaches revealed 
new opportunities to control the degradation of alginates (Lee et al., 2000), more efforts are 
needed to translate these gels into the clinics.  
Chitosan is a polysaccharide forming the exoskeleton of many seashells. As it is mainly 
comprised of glucosamine, a component of cartilage extra-cellular matrix (ECM), chitosan is 
an attractive biomaterial for regenerative therapies of the skeletal system (Chenite et al., 
2000; Madihally and Matthew, 1999). Its positive charge allows complexation with other 
negatively charged ECM proteins present in articular cartilage like glycosaminoglycans. 
This would induce in vivo sequestration of growth factors embedded in the surrounding 
cartilaginous ECM. Chitosan can be processed in the form of a gel exploiting its pH-
dependent solubility, drawn into solid fibers, or foamed by freeze-drying (Chenite et al., 
2000; Yamane et al., 2005). This processing versatility enables the fabrication of scaffolds 
with fine-tunable mechanical properties. Although the intrinsic batch-to-batch variability 
during chitosan extraction is still a major drawback, its physical, mechanical, and biological 
properties are promising for articular cartilage regeneration.  
Hyaluronic acid is a highly hydrophilic proteoglycan present in the extra-cellular matrix 
(ECM) of several tissues. In cartilage, it contributes to maintain homeostasis and physical 
integrity thanks to its viscosity, capacity to retain water, and interactions with chondrocytes 
and other ECM proteins. When used as a biomaterial, hyaluronic acid can be covalently 
cross-linked or esterified to improve its mechanical properties and physical stability. In the 
latter case, hylans are formed. These biomaterials are currently used in the clinics as 
hydrogels or membranes to assist in autologous chondrocyte implantation (Brun et al., 1999; 
Campoccia et al., 1998; Hollander et al., 2006). Yet, the less-than-optimal mechanical 
properties and the potential presence of endotoxins and impurities are drawbacks that still 
need to be improved to consider these biomaterials a fully viable alternative to synthetic 
polymers. Furthermore, hyaluronic acid is present in high concentrations in the surrounding 
tissues of malignant tumors (Knudson et al., 1989). This evidence should be further studied 
to ensure that no risks are associated with the use of hyaluronic acids or its derivatives as 
biomaterials.  
Collagen is one of the extra cellular matrix protein most used to form natural hydrogels. It is 
easy to obtain from different sources as it is the most common protein present in numerous 
tissues and organs. Jellification typically occurs through thermally reversible physical cross-
links. These gels can be easily remodeled through production of collagenases by 
encapsulated cells, thus offering the opportunity to study cell-matrix interactions during 
tissue development (Mueller et al., 1999; Pachence, 1996; Nehrer et al., 1997). Collagen gels 
can also be formed in the presence of other proteins such as chondroitin sulphate or 
hyaluronic acid, so that the resulting semi-interpenetrating network can be functionalized to 
display biological moieties of interest in cartilage regeneration. Gelatin, a derivative of 
collagen formed by breaking its natural triple-helix structure, has also been used as a 
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hydrogel for cartilage regeneration (Choi et al., 1999). The main drawbacks of collagen and 
its derivatives lye in the potential immunogenic risks due to its origin, batch variation, and 
poor mechanical properties. Chemical cross-linking strategies by exposure to 
glutaraldehyde or genipin confer enhanced physical stability and mechanical properties to 
the resulting hydrogels, however without reaching similar stiffness to that of articular 
cartilage. 
Synthetic hydrogels. Among synthetic hydrogels, a number of derivatives based on 
poly(ethylene glycol) (PEG) have been developed and used for cartilage tissue engineering. 
This biomaterial is relatively inert, highly hydrophilic, and very versatile for the 
functionalization of its backbone with different biological moieties. PEG is known to have 
anti-fouling properties and is often used in vascular applications as a coating to prevent 
thrombogenesis. PEG can be synthesized either as a linear, branched, or star-shaped 
polymer. In its star-shaped form, different peptides or growth factors can be coupled 
depending on the number of arms. These biological factors can be covalently linked to the 
PEG chains through passive or active linkers comprised of an enzymatically sensitive 
peptide sequence, thus being able to release the payload depending on cellular activity 
(Adelow et al., 2008; Lutolf et al., 2003). PEG or its oxidized version poly ethylene oxide 
(PEO) can also be grafted to other polymers such as poly propylene oxide (PPO) or poly 
lactic acid (PLA). PEO-PPO-PEO is a tri-block copolymer, also commercially known as 
pluronic®, that jellifies through a temperature sensitive phase change. These copolymers 
have been conventionally used as drug delivery vehicles and recently also explored in tissue 
engineering applications for skeletal regeneration (Fedorovich et al., 2009; Park et al., 2009; 
Batrakova and Kabanov, 2008). Yet, PEO-PPO copolymers are not degradable limiting their 
potential use. PEG-PLA copolymers have been synthesized for tissue engineering 
applications. Gelation occurs via stereocomplexation of L- and D-lactic acid. By changing 
the molecular weight of the PLA and PEG blocks, it is possible to vary the mechanical 
properties of the resulting gels. Proteins and other biological factors can be easily 
incorporated during gelation in these degradable hydrogels, conferring them a high 
versatility and potential for clinical applications (Hiemstra et al., 2006a; Hiemstra et al., 
2006c). An alternative derivative of PEG is synthesized by linking acrylate groups to the 
main chain. PEG-diacrylate (PEGDA) is a photopolymerizable hydrogel that cross-links in 
presence of an initiator under UV light. PEGDA has been extensively used in cartilage tissue 
engineering as an inert encapsulating system or after modification with different peptides, 
growth factors, or in semi-interpenetrating networks with ECM proteins (Hwang et al., 2006; 
Lee et al., 2006; Sharma et al., 2007). It is a reproducible hydrogel system with fine-tunable 
physicochemical and mechanical properties that enable tissue regeneration without the 
potential risks associated to natural polymers, thus making it a promising candidate for 
clinical use. 
3.2 Solid polymers  
Within solid polymers, poly lactic acid (PLA), poly glycolic acid (PGA) and copolymers 
(PLGA) have been broadly used in tissue engineering as well as for cartilage regeneration 
(Anderson and Langone, 1999; Babensee et al., 2000; Chu et al., 1997; Freed et al., 1993; 
Honda et al., 2000; Sarazin et al., 2004). These biomaterials are approved by the food and 
drug administration (FDA) as they activate a minimal or mild foreign body reaction, and as 
such are considered biocompatible. The mechanical properties and degradation rate can be 
www.intechopen.com
 Joint Cartilage Tissue Engineering and Pre-Clinical Safety and Efficacy Testing 
 
187 
tailored by varying the molecular weight and copolymer ratio. They have already been 
studied for drug delivery (Jang and Shea, 2003; Uhrich et al., 1999; Richardson et al., 2001; 
Nof and Shea, 2002; Sengupta et al., 2005) and are suitable for tissue engineering 
applications, as the degradation products (lactic and glycolic acids) obtained due to 
hydrolysis are normally present in the metabolic pathway and can be naturally eliminated 
by the body. However, their bulk degradation may be associated with the formation and 
accumulation of large amounts of degradation products in a short time frame (months vs. 
years) that cannot be easily discarded, resulting in local inflammation in tissues (Bostman et 
al., 1989) and enzymatic hydrolysis (Fu et al., 2000). Another polyester commonly used in 
tissue engineering is poly ε-caprolactone (PCL). This polymer is characterized by good 
biocompatibility and mechanical properties. It degrades at a much slower rate than PLA, 
PGA, and PLGA, which makes it attractive when long-term implants and controlled release 
applications are desired (Honda et al., 2000; Wang, 1989; Hutmacher et al., 2001; Choi and 
Park, 2002). It has been also shown that PCL can selectively adsorb vitronectin, a protein 
that is known to facilitate stem cell chondrogenic differentiation. Conversely, PLA 
selectively adsorb fibronectin and seems to be better suited to induce stem cell osteogenic 
differentiation. A different family of thermoplastic polymers that has been investigated for 
tissue engineering is poly ethylene oxide terephthalate-co-poly butylene terephtalate 
(PEOT/PBT). These polyether-ester copolymers possess good physical properties like 
elasticity, toughness and strength (Bezemer et al., 1999). By varying the molecular weight of 
the starting PEG segments and the weight ratio of PEOT and PBT blocks, it is possible to 
tailor physico-chemical and mechanical properties (Bezemer et al., 1999; van Dijkhuizen-
Radersma et al., 2002; Deschamps et al., 2002; Olde Riekerink et al., 2003; Woodfield et al., 
2004; Moroni et al., 2006b), degradation rate (Deschamps et al., 2002), and protein 
adsorption (Mahmood et al., 2004). PEOT/PBT copolymers have been demonstrated to be 
biocompatible both in vitro and in vivo for skin, cartilage, and bone regeneration (Malda et 
al., 2004; van Blitterswijk et al., 1993; Bakker et al., 1988; Beumer et al., 1994a; Beumer et al., 
1994b). A further modulation in degradation rate and drug release profile can be achieved 
by substituting part or all of the terephtalate domains with succinate blocks during the 
copolymerization reaction (van Dijkhuizen-Radersma et al., 2003; van Dijkhuizen-Radersma 
et al., 2004; van Dijkhuizen-Radersma et al., 2005). PLA, PGA, PLGA copolymers, PCL, and 
PEOT/PBT copolymers have proven to be interesting biomaterials to fabricate 3D scaffolds. 
Although their properties can be customized for specific purposes, some concerns over their 
degradation mechanism and rate still remain.  
To obviate bulk degradation, surface eroding polymers have been developed such as 
polyortho-esters (POEs) (Choi and Heller, 1978), polyphospho-esters (PPEs) (Wang et al., 
2001a; Wang et al., 2001b), and polyanhydrides (PAs) (Leong et al., 1986). Surface erosion is 
a degradation mechanism (Andriano et al., 1999; Burkoth et al., 2000), which affects the 
stability of the scaffolds to a lesser extent and elicits a lower in vivo inflammatory response, 
as compared to polyesters and polyether-esters previously considered. PPEs display 
adequate mechanical properties also for hard tissue engineering. Although PPAs, PAs, and 
POEs have been used in some cases for hard tissues repair, they might be more suitable for 
soft tissue engineering due to their generally low mechanical properties. More recently, 
PLA based polymers modified with photosensible chemical groups like fumarates or 
acrylates have been developed for biomedical applications (Melchels et al., 2009; Melchels 
et al., 2006). These biomaterials offer the advantage of being processed by rapid 
prototyping technologies with high resolution, thus enabling the fabrication of 
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sophisticated scaffold geometries. Yet, some issues may still arise from remnant toxicity 
due to the acrylic groups.  
3.3 Scaffold fabrication technologies 
A plethora of fabrication technologies have been developed and characterized to fabricate 
three-dimensional (3D) scaffolds for tissue engineering applications (Figure 2). Although 
these techniques can also be applied to hydrogels, they have been mostly used with solid 
polymers due to the intrinsic advantage of the former as a minimally invasive injectable 
biomaterial. Foams and textiles are the two predominant types of scaffolds used in tissue 
engineering. Foams can be fabricated by gas foaming, freeze drying, or porogen leaching 
(Barry et al., 2004; Sproule et al., 2004; Schoof et al., 2001; Ma and Zhang, 2001; Claase et al., 
2003; Sarazin and Favis, 2003). Textile scaffolds can be produced by wet or melt spinning, 
creating fibers that are randomly deposited on top of each other, woven, or knitted (Cima et 
al., 1991; Freed et al., 1994; Niklason and Langer, 1997). Once deposited, thermal or chemical 
treatments can be applied to improve fiber bonding, thus enhancing structural stability and 
mechanical properties (Kim and Mooney, 1998a; Kim and Mooney, 1998b; Mikos et al., 
1993). These methods are relatively easy to implement, but offer a limited control over 
mechanical properties, interconnectivity of of pore network, pore size and shape, and 
porosity. It has recently been shown that scaffolds mimicking the structural and 
architectural characteristics of the targeted tissue support enhanced tissue formation, and 
fabrication technologies that enable a fine control over scaffold pore network and strut size 
are needed. In the specific case of articular cartilage, three different zones can be 
distinguished: (i) deep, (ii) middle, and (iii) surface zones. In each of these regions, the 
alignment of collagen type II is distinct and results in the overall arch-like architecture 
typical of articular cartilage. Furthermore, chondrocytes behave in a different manner and 
are responsible for the production of different extra-cellular matrix proteins, namely 
different proteoglycans, depending on the zone where they are located (Klein et al., 2009; 
Klein et al., 2003; Schuurman et al., 2009). This has lead researchers to focus their attention 
on technologies that enable the fabrication of layer-by-layer scaffolds. This would enable not 
only a better control of different cartilage zones, but also the construction of more complex 
tissue such as osteochondral grafts. A simple and effective solution is to cross-link 
monolithic hydrogel regions containing chondrocytes of the different regions or other cells 
on top of each other (Elisseeff et al., 2002; Lee et al., 2008; Hwang et al., 2007).  
Where a better control over cell and tissue spatial distribution is desired, rapid prototyping 
(RP) technologies offer an appealing solution. RP is based on computer aided design (CAD) 
and computer aided manufacturing (CAM) to build porous 3D scaffolds in a layer-by-layer 
controlled manner. An extensive number of biomaterials can be processed by these 
techniques in a custom-made shape (Hutmacher, 2001; Yang et al., 2002; Yeong et al., 2004), 
with tailored mechanical properties to the specific application considered (Hollister, 2005; 
Taboas et al., 2003; Lin et al., 2004). The outcomes are 3D scaffolds that possess fine-tunable 
porosity, pore size and shape, and have a completely interconnected pore network, which 
permits a better cell migration and nutrient perfusion than 3D scaffolds fabricated with 
more conventional techniques like foaming or spinning (Malda et al., 2004; Sachlos and 
Czernuszka, 2003). In addition, the fabrication of personalized scaffolds can be envisioned 
with the acquisition and processing of computer tomography (CT) and/or magnetic 
resonant imaging (MRI) anatomical data from patient datasets (Hollister, 2005; Moroni et al., 
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2007a). Since RP is based on layer-by-layer processing, it is also theoretically possible to 
change the pore network structural and architectural characteristics in space in order to 
better mimic specific ECM and cell spatial arrangement. In practice, this has not been 
extensively explored. Moroni et al. (Moroni et al., 2006a) have been active in studying how 
mechanical properties can be optimized with different pore networks for the regeneration of 
different types of cartilage. Similarly, Woodfield et al. (2005) produced scaffolds with pores 
varying along the longitudinal axis in the attempt to mimic the spatial distribution of 
chondrocytes in articular cartilage. Oh et al. (2010) used a similar approach and fabricated 
scaffolds with different pore size ranges by a more conventional freeze-drying method. In 
these scaffolds, chondrogenic differentiation in adipose derived mesenchymal stem cells 
was better supported with pores in the 370-400 µm range. The resulting scaffolds showed 
enhanced tissue formation, while cell and ECM distribution resembled more closely that of 
native hyaline cartilage. By combining different materials, it was also possible to fabricate 
osteochondral constructs that functionally supported both bone and cartilage regeneration 
(Moroni et al., 2008; Sherwood et al., 2002).  
From these studies it is clear that 3D scaffolds fabricated by RP offer many advantages and a 
broad flexibility as a model to study new strategies for tissue engineering. However, they do 
not possess biologically active properties to improve communication with the adhered or 
encapsulated cells. This can be achieved by two means: (i) implementing drug delivery 
vehicles into the scaffolds, (ii) improving the fabrication resolution to achieve true synthetic 
ECM substitutes. In the former case, biological factors have been encapsulated or covalently 
linked into hydrogels (Ehrbar et al., 2007; Saha et al., 2007; Kong and Mooney, 2007) or 
incorporated into microspheres and fibers (Martins et al., 2010; Richardson et al., 2001), 
which were directly used for tissue engineering applications (see Delivery Methods section). 
Controlled drug delivery strategies showed to improve cartilage regeneration when 
combined with 3D scaffolds. However, local and spatial control over the release of biological 
factor is still lacking and might contribute to better mimic the native tissue architecture 
during regeneration. In the latter case, 3D scaffolds with feature dimensions in the range of 
ECM have been recently fabricated by two-photon polymerization (2PP). This technology 
exploits in situ polymerization of photosensible polymers at specific wavelengths 
(Ovsianikov et al., 2011). With 2PP, a number of rather complex structures can be fabricated 
with nanometric resolution (Ovsianikov et al., 2010). These can be interesting tools to study 
fundamental cell-material interaction at a single cell level, but the fabrication time window 
might be too long when clinically relevant scaffold dimensions are needed. An alternative 
technique that has been extensively used to mimic the ECM of tissues is electrospinning 
(ESP). Here, fiber meshes are fabricated by spinning a biomaterial solution into an electric 
field that destabilizes the solution flow and form a continuous jet of fibers collected on a 
target plate. The fiber deposition architecture can be modified depending on the geometry 
and electric properties of the collector plate (Zhang and Chang, 2008; Zhang and Chang, 
2007). ESP has been used with a large number of biomaterials (Li and Xia, 2004) and also 
enables the incorporation of growth factors, proteins, or cells during fabrication (Li et al., 
2006a; Patel et al., 2008). The fabricated scaffolds possess physical and surface properties 
that have already been shown to support cartilage tissue engineering (Li et al., 2006b; Li et 
al., 2005). These meshes may suffer from a lack of cell penetration due to the high fiber 
density and small pore size. However, spinning of more biomaterials with different 
degradation rate can obviate this. Virtually, water-soluble biomaterials would allow a fast 
degradation and a better infiltration of cells into the scaffold pores.  
www.intechopen.com
  
Tissue Engineering for Tissue and Organ Regeneration 
 
190 
 
Fig. 2. Scaffold fabrication technologies. Different scaffold fabrication technologies can be 
used to create 3D porous biomaterials for tissue engineering applications. (I) Conventional 
foams can be obtained by (I-A) salt leaching or (I-B, I-C) by inverted colloidal crystal (ICC) 
template. In both case a porogen material is used to form a defined volume with the selected 
biomaterial and later removed through selective dissolution. In case of ICC, the resulting 
pore network is improved in terms of interconnectivity and (C) cell seeding efficiency (cells 
green fluorescent). (I-D) Textile scaffolds can be fabricated by rapid prototyping 
technologies. (I-D) Here, a meniscus shaped scaffold is shown. Insets display different fiber 
deposition methods, which affect the formed pore size and shapes. Not only solid polymers, 
but also hydrogels can be processed (no picture shown but available at Landers et al (2002) 
(Landers et al., 2002). (II) ECM mimicking meshes can be fabricated by electrospinning. (III-
A) The electrospun fibers typically have a smooth surface, but (II-B) depending on the 
solvent used can also display different surface morphologies. Panel (I-A, I-B, I-C) modified 
by Deschamps et al (2002) and Nichols et al. (2009). Panel (I-D) modified by Moroni et al 
(2007). Panel (II) modified by Moroni et al. (2008)  
4. Cytokines release 
Cartilage engineering is not only a result of cells and scaffolds coming together to form a 
’cartilage-like’ structure. As mentioned earlier there are two relevant cell choices – 
chondrocytes and MSCs. Chondrocytes need to be in an environment resembling the 
physiological properties of cartilage to maintain their phenotype. MSCs will need to go 
www.intechopen.com
 Joint Cartilage Tissue Engineering and Pre-Clinical Safety and Efficacy Testing 
 
191 
through the process of chondrogenesis. Chondrogenesis is an intricate process where MSCs 
go through stages of differentiation to become fully matured chondrocytes (Figure 3). Only 
when the cells have committed to the chondrogenic fate will they start to lay down cartilage-
type extracellular matrix (ECM). The differentiation process involves a range of stage 
specific molecules that include phenotypic determinants, adhesion molecules, and signalling 
molecules as described in great detail by Chen et al. (2009). 
 
 
Fig. 3. Chondrogenic differentiation. Chondrogenesis is an intricate process where MSCs go 
through stages of differentiation to become fully matured chondrocytes. Members of the 
TGF-β superfamily and IGF-1 are examples of important regulators in the differentiation 
process. Figure by L. C. Berg 
When attempting to produce tissue that resembles true cartilage both chondrocytes and 
MSCs will need the right molecular signals. Differentiation can be promoted by adding 
chondrogenic cytokines and growth factors to the construct. Some of the major players in 
the intricate network of chondrogenic cell signalling are well described in the literature, but 
other members are only known in very little detail or not at all. There is no question we still 
have much to learn, before we fully understand the temporal and spatial importance of the 
cytokines and growth factors involved in cartilage synthesis. However, studies have shown 
that even a simpler version with addition of only a few key molecules will strongly increase 
the quantity and quality of cartilage-like tissue produced. 
In the following sections, we will present some of these key factors currently being used in 
cartilage engineering, and the delivery methods available. 
4.1 Growth factors 
4.1.1 Transforming growth factor-β superfamily  
The transforming growth factor-β (TGF-β) superfamily includes the TGF-β and the bone 
morphogenetic (BMP) proteins. The most well described family members in relation to 
cartilage tissue engineering are TGF-β1, TGF-β3, BMP-2 and BMP-7 (also known as 
osteogenic protein-1 (OP-1)), but other members may prove to be equally important.  
TGF- β1, TGF-β2, and TGF-β3 have all been shown to be chondrogenic in vitro on MSCs 
(Kulyk et al., 1989; Blunk et al., 2002). They are believed to be involved in the early stages of 
the differentiation process (Chen et al., 2009). In vitro they are known to stimulate synthesis 
of ECM including collagens, fibronectin (Ignotz and Massague, 1986), and proteoglycans 
(Chen et al., 1987), and decrease the expression of collagen type 1 in MSCs (Kurth et al., 
2007). Studies on human MSCs have shown that TGF-β2 and TGF-β3 are more chondrogenic 
than TGF-β1 (Barry et al., 2001; Chen et al., 2009). 
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Unfortunately, the very promising results with TGF-β from in vitro studies have not been 
reproduced in animal models. In mice and rabbits intra-articular administration of TGF-β 
has been shown to have a number of side effects including inflammation and osteophyte 
formation (Bakker et al., 2001; van Beuningen et al., 2000). These side effects appear to be 
linked to the non-cartilaginous tissues of the joint (Blaney Davidson et al., 2007a; Scharstuhl 
et al., 2002), and can potentially be prevented if the growth factor only comes into contact 
with the cartilage. 
The BMPs involved in chondrogenesis include BMP-2, -3, -4, -5, -6, -7, and -9. They support 
chondrocyte phenotype and stimulate synthesis of proteoglycans (Li et al., 2003; Sailor et al., 
1996). BMP-2, and -7 have been shown to be the more chondrogenic of the BMPs in MSCs in 
vitro (Majumdar et al., 2001; Sekiya et al., 2005; Fan et al., 2010), and both have shown 
promising results in animal models (Badlani et al., 2009; Blaney Davidson et al., 2007b). The 
chondrogenic effect of BMP-7 is synergistically increased when used in combination with 
TGF-β (Xu et al., 2006; Kim and Im, 2009) or insulin-like growth factor (IGF)-1 (Loeser et al., 
2003; Chubinskaya et al., 2007a). BMP-2 is also a strong inducer of osetogenesis and is used 
clinically for bone fusion (Tang et al., 2011; Hamilton et al., 2011), which needs to be taken 
into consideration if using BMP-2 for cartilage generation. Only BMP-2 and BMP-7 are 
currently approved for clinical use in human patients (Haleem and Chu, 2010). 
In addition to the TGF-βs and BMPs, this large family of molecules also includes activin and 
growth differentiation factor 5 (GDF5) that have been shown to be chondrogenic inducers in 
MSCs (Jiang et al., 1993; Bai et al., 2004). 
4.1.2 Insulin-like growth factor-1 
IGF-1 is primarily synthesized in the liver regulated by growth hormone (GH). The 
responsiveness of cells to IGF-1 decreases with age and osteoarthritis (Boehm et al., 2007; 
Loeser et al., 2002). IGF-1 is capable of inducing chondrogenesis in MSCs on its own, but it is 
much more effective in combination with other growth factors e.g. TGF-β (Longobardi et al., 
2006) and BMP-7 (Loeser et al., 2003; Chubinskaya et al., 2007b).  
4.2 Delivery methods 
Most growth factors and cytokines have short half-lives (Nimni, 1997), and their effect 
would therefore be limited to the time right after implantation of the construct. Subsequent 
supplementary treatments entail several risks depending on the choice of route of 
administration.  
Systemic delivery presents a number of potential problems. Since the amount of active 
reagent actually reaching the site of interest will be a fraction of the initial dose, the 
administered dosage will have to be up regulated. This will increase both the cost of 
treatment and the risk of adverse reactions. In route to the target site the growth factors and 
cytokines will come into contact with a number of other tissues, where they may cause 
undesirable effects. Local injection into the construct provides a more controlled 
administration, but repeated joint injections are not desirable due to the risk of infection and 
added cost to the patient.  
Because of these issues, a number of delivery systems have been developed and tested, 
where growth factors and cytokines are released into the local environment of the construct 
in a time and dose controlled manner. Some of these delivery systems are closely linked to 
the scaffold materials, and may not work well with all types of scaffolds. Other systems are 
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linked to the cells. A requirement for the successful delivery system is that the active 
molecules are protected against degradation until time of release. The systems range from 
very basic soaking of the scaffold in growth factor suspension (Kanematsu et al., 2004) to 
highly sophisticated release systems, where attempts are being made to closely mimic the 
stage specific differentiation process or even create dual tissues by releasing different 
molecules at controlled time points, dosages, and locations in the scaffold (Wang et al., 2009; 
Suciati et al., 2006). These highly complex systems are still in their infancy. 
4.2.1 Direct attachment or incorporation  
The simplest version of delivery system is a direct attachment of growth factor to the surface 
of the scaffold material by soaking the scaffold in growth factor suspension (Kanematsu et 
al., 2004), or incorporation of the growth factors and cytokines into biodegradable scaffolds, 
usually hydrogels (Yamamoto et al., 2001; Nelson et al., 2011). The factors are then released 
passively from the surface of the scaffold or as the scaffold degrades. Current applications of 
hydrogels primarily include drug delivery, since the scaffolds are too soft to play the 
structural role needed in cartilage constructs (Woodfield et al., 2002). 
Molecule bound. Another way of incorporating growth factors and cytokines in scaffolds is to 
bind them to intermediary components in the construct. This method may prolong the effect 
of the growth factors by slowing down the release process. A study in rabbits using MSCs, 
elastic block copolymer scaffolds and TGF-β3, showed that chondroitin sulphate-bound 
TGF-β3 had a slower release profile than TGF-β directly incorporated into the scaffold (Park 
et al., 2010). Similar results have been achieved by binding TGF-β3 (Park et al., 2008) or bFGF 
(Jeon et al., 2006) to heparin.  
Loaded structures. The cytokines can also be delivered to the constructs in loaded structures. 
Microspheres (Kim et al., 2003; Elisseeff et al., 2001; Fan et al., 2007; Fan et al., 2004), 
liposomes (Hunziker et al., 2001), and micro sponges (Fan et al., 2010) loaded with growth 
factors have all been tested in studies in cartilage tissue engineering. Their advantage is a 
more controlled release rate, while the growth factors are kept relatively protected from 
their surroundings thus preserving their activity. 
Gene therapy. A different approach to delivery of growth factors and cytokines important to 
chondrogenesis is to make the MSCs themselves produce the factors necessary to the 
cartilage construct. This can be achieved by using gene therapy techniques. The use of gene 
therapy in cartilage tissue engineering has been thoroughly reviewed by Steinert et al. 
(2008). Here, we will simply provide a short introduction to the concept. There are several 
different methods available ranging from a simple direct delivery of genetic material at the 
defect site to complex procedures implemented as part of the cartilage engineering process. 
No matter which method is used, the most important factors in gene therapy are related to 
how well the gene material is transferred to the target cell, and how efficient the now 
transgenic cells are at producing the desired molecules. 
The gene therapy techniques fall into two categories – in vivo and ex vivo techniques. 
Common to them is the need for good vectors. These can be non-viral or viral. The non-viral 
vectors are safer but less efficient, while the viral vectors are more efficient but pose a 
potential safety risk especially if they are injected into the patient (Steinert et al., 2008). 
In vivo delivery is the cheaper option, where vectors harbouring the gene material are 
introduced to the cells directly at the site of injury. This method is simple and fast, but it is 
difficult to control the efficacy of transfer as well as the safety of the procedure. Especially if 
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viral vectors are used there is a risk of the vectors inserting themselves into the genetic 
material of host cells in the area. The in vivo method is particularly useful in tissues where it 
is not possible to remove cells for ex vivo transfection. Its use in studies on cartilage repair 
has been very limited. The ex vivo method is more time consuming, expensive, and 
technically challenging. The genetic material is transferred to the cells, before the cells are 
used in the patient. Using this method makes it possible to test transfection rate, and the 
risks associated with use of viral vectors are eliminated. Ex vivo gene transfer has been 
tested in a number of studies involving MSCs and cartilage tissue engineering. MSCs 
transfected with BMP-7 yielded better cartilage repair than non-treated control cells (Mason 
et al., 2000). Similarly, gene induced expression of TGF-β1 and BMP-2 promoted 
chondrogenesis in MSCs, while induced expression of IGF-1 did not (Palmer et al., 2005). A 
subsequent study from the same group showed that the use of combinations of those three 
chondrogenic genes had a strong synergistic effect on chondrogenesis (Steinert et al., 2009). 
5. Mechanical stimuli and bioreactors 
During daily activities, the cartilage is exposed to direct compression, hydrostatic pressure, 
or shear. It has been suggested that mechanical loading may increase extracellular matrix 
(ECM) synthesis during cartilage engineering (Portner et al., 2009). The hypothesis that 
mechanical stimulation enhances cartilage formation is based on studies of developmental 
biology where restriction of joint loading after birth leads to poor post-natal cartilage 
adaptation (Williamson et al., 2003a; Williamson et al., 2001; Williamson et al., 2003b; Mikic 
et al., 2004; Mikic et al., 2000). Overall, mechanical stimulation leads to increased cell 
expansion as well as increased extracellular matrix proteins production compared to regular 
static cultures (Portner et al., 2009).  
A bioreactor is defined as any device in which a biological/biochemical process is 
performed under controlled conditions. When compared to static cultures, bioreactors offer 
a number of advantages such as uniformed distribution and increased mass transfer, control 
of pH, temperature, gas supply (O2 and CO2), nutrients, waste product removal, and the 
opportunity to incorporate mechanical stimuli. Detailed reviews on the general concepts of 
bioreactors for tissue engineering and the application of bioreactors for the purpose of 
cartilage engineering are available (Godara et al., 2008; Chen et al., 2006; Chung and 
Burdick, 2008; Portner et al., 2009; Haasper et al., 2008; Huang et al., 2010b; Schulz and 
Bader, 2007; Concaro et al., 2009; Grad et al., 2011). Selected physical outcome parameters 
used in cartilage engineering in defined and described in Text Box 1.  
Bioreactors for cellular therapeutic use have being grouped into two categories. Bioreactors 
for tissue engineering and bioreactors for cell infusion therapies. However, the simpler 
systems used for infusion therapies have also been utilized for tissue engineering purposes 
due to ease and cost. Bioreactors for isolation and expansion of cells for cell infusion 
therapies are largely similar to or adapted from pharmaceutical monoclonal antibody 
production systems or industrial yeast-based methods. Spinner flasks and rotating wall 
vessels are examples of bioreactors for cell expansion (Concaro et al., 2009). In spinner flasks 
a magnetic stir bar moves the medium. The media movement provides the cell-scaffold 
constructs with nutrients and oxygen and facilitates waste removal by overcoming the 
normal diffusion limit of 100-200 μm. In this system a balance has to be struck between 
homogenous mass transfer including uniform pH gradient and shear gradients that can 
cause cell damage. Stirring at 50 rpm is a common starting point (Concaro et al., 2009). If the 
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speed of the rotating outer wall of rotating wall vessels is calibrated to the mass of the cell 
carrier constructs, then a microgravity environment is created where the cells are exposed to 
low shear stress and high mass transfer. However, hitting this “soft spot” of equilibrium can 
be challenging and failure hereof may lead to shear stress and constructs colliding with the 
walls, which adversely affect cell function (Concaro et al., 2009). However, rotating wall 
vessels have been utilized to study microgravity’s effect on cartilage tissue engineering both 
on Earth and in space (Vunjak-Novakovic et al., 2002; Marolt et al., 2006). Marked 
differences where noted between cartilage engineered on Earth and in space, on Mir, 
confirming that physical forces modulate musculoskeletal tissue such as cartilage (Vunjak-
Novakovic et al., 2002). Bioreactors for cartilage engineering have largely been used to 
evaluate response to compression, but bioreactors applying electrical fields, ultrasound, 
centrifugal forces, shear forces, perfusion of 3D constructs, tension of cell layers, hydrostatic 
pressure, and hydrostatic pressure with perfusion have also been reported (Schulz and 
Bader, 2007). These bioreactors are mostly custom made, but an increasing number of 
commercial bioreactors are becoming available for various purposes (Yeatts and Fisher, 
2011). Comparison between research groups is therefore exceedingly difficult. One major 
concern with many of the studies is the validation of the bioreactor prior to use and the 
continued calibration. Thorough evaluation and validation of the bioreactors prior to and 
continuously through their use by applying objective measurable parameters is critical in 
order to evaluate the results and conclusions. Many of the bioreactors can only stimulate the 
tissue and have limited, if any, possibilities of sampling and analyzing the tissue or culture 
medium without terminating the culture process.  
Most cartilage bioreactor studies have reported work using uniaxial direct compression 
(Grad et al., 2011). A general starting point for direct compression studies of cells adhered to 
a scaffold is 10% or 15% compression at a frequency of 1Hz (Grad et al., 2011; Terraciano et 
al., 2007; Mouw et al., 2007; Huang et al., 2004).  Recently, mechanical stimulation showed 
improved cartilage formation of porcine chondrocyte cartilage constructs compared to static 
culture, but no difference was noted between perfusion and perfusion-compression 
constructs (Tran et al., 2011). In the compression group, constructs where cultured with 
perfusion alone at a flow rate of 0.5ml/min for the first week followed by 1 Hz sinusoidal 
unconfined compression, 4 hours a day, 5 days a week, starting with a load of 0.5 N until 20 
N by the third week (Tran et al., 2011). Perfusion was maintained in this compression group 
for the 4-week duration of the study and compared to a control group of perfusion only. 
Biochemistry revealed a higher glycosaminoglycan (GAG) content, but a lower collagen 
content in the bioreactor construct compared to native cartilage. The discrepancy between 
GAG and collagen content could be due to enzymatic collagen degradation or simply reflect 
immature cartilage since rabbit studies have shown that the cartilage collagen network does 
not mature until 3 months of age (Julkunen et al., 2009; Riesle et al., 1998). Rabbit joint 
cartilage at birth is homogenous with collagen fiber alignment parallel to the surface, but as 
the cartilage matures the collagen fibers organize into the three zones seen in adult cartilage 
(Julkunen et al., 2011). However, the specific cartilage organization and biochemical content 
differ from joint to joint and even between opposing joint surfaces of the same joint 
(Julkunen et al., 2011). Recently, bovine bone marrow (BM) derived MSCs exposed to long-
term dynamic compression in chondrogenic culture were shown to exert improved 
mechanical properties compared to static culture as previously reported in studies of 
chondrocyte cultures (Huang et al., 2010a). Interestingly immediate mechanical stimulation 
of cartilage constructs appear detrimental and a more physiological approach of initial stem 
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cell chondrogenic differentiation using TGF-β without mechanical stimulation, as in utero, 
followed by mechanical stimulation, as post-natal, appear more effective (Terraciano et al., 
2007; Mouw et al., 2007; Thorpe et al., 2008). These observations would concur with the 
observations of normal rabbit joint cartilage development as described above, where the 
cartilage at birth is a homogenous structure that remodels post-natally in response to 
loading.  
Hydrostatic pressure in cartilage tissue engineering has been reviewed elsewhere (Elder and 
Athanasiou, 2009). Hydrostatic pressure does not exert any measurable strain on the cell 
and the mechanistic effect are believed to be mediated through deformation of 
transmembrane ion transport proteins leading to increased intracellular calcium 
concentrations (Schulz and Bader, 2007; Kornblatt and Kornblatt, 2002; Elder and 
Athanasiou, 2009). The effect of hydrostatic pressure is incompletely understood, but both 
dynamic and static pressure has been investigated in both normal chondrocytes, 
osteoarthritic chondrocytes and as a mean for chondrogenic cell differentiation (Elder and 
Athanasiou, 2009).  Physiological hydrostatic pressure of 5-10 Mpa are generally anabolic 
when applied in a dynamic fashion to both 2D and 3D chondrocyte layers, but if static 
pressure is applied anabolic effect is only noted in 3D layers (Elder and Athanasiou, 2009).  
Such physiological loads can also promote stem cell differentiation, chondrocyte 
redifferentiation, and exert chondroprotective effects and osteoarthritic chondrocytes (Elder 
and Athanasiou, 2009). Super-physiological pressures (20-50 Mpa) are particular detrimental 
to cell metabolism if applied for more than 2 hours (Elder and Athanasiou, 2009). Schulz and 
Bader have reviewed the mechanism of hydrostatic pressure stimulation and why 
prolonged loading leads to cartilage damaged (Schulz and Bader, 2007). Interestingly, 
compression likely acts through hydrostatic pressure as well. The reason is that negatively 
charged proteoglycans provide frictional resistance by binding water and preventing the 
water from being squeezed out of the tissue. The net effect is increased hydrostatic pressure 
within the tissue. However, the water does shift out of the tissue if the pressure persists. In 
this case, the load is increasingly carried by the collagen fibers until the fibers are orientated 
parallel to the load direction. Load beyond this point leads to tearing of the collagen 
network.  
One trend in cartilage bioreactor design is towards a more tribological approach, where the 
science and technology of interacting surfaces in relative motion is used to develop multi-
axial bioreactors that more closely mimic the movement of a natural joint (Figure 4) (Grad et 
al., 2011). Multiaxial compression and shearing stimulation represent more closely in vivo 
conditions and are associated with broader chondrogenic gene expression profiles 
compared to uniaxial compressive loading (Grad et al., 2011). Another trend is the ability of 
bioreactors to simultaneously provide mechanical stimuli and evaluate the physical 
properties of the developing tissue (Portner et al., 2009).  The ability to monitor the construct 
as it develops allows for a reduction in sample size since temporal changes can be assessed 
on the same sample. It may even be possible to perform online temporal molecular 
evaluation of the cells, the conditioned culture medium and extracellular matrix 
composition and responses in closed bioreactor system through the application of high-
resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR), matrix-
assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF MS), 
combinatory phase sensitive scanning acoustic microscopy (PSAM), and confocal laser 
scanning microscopy (Schulz and Bader, 2007). Such advanced bioreactors can be valuable 
tools in preconditioning cell-scaffolds prior to clinical research use as well as model systems 
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for in vitro evaluation of cell response to a variety of physical as well as chemical stimuli. 
These systems may also have value as model systems to reduce the number of animals used 
for in vivo studies by allowing replacement and refinement prior to in vivo studies. 
However, their utility for commercialization of tissue replacement strategies may be 
hampered by high production costs and violation of GMP due to the often semi-sterile 
productions systems.  
 
 
Fig. 4. Advanced bioreactor. (A) Advanced tribological bioreactor capable of multiaxial 
stimulation of tissue-engineered constructs. Each chamber can be individually controlled to 
simulate the movements of complex joints, e.g. the knee (b and C) Reprinted with 
permission from Grad et al. (2011)  
Soft lithography produced microfluidic bioreactors have been advocated as the next 
generation of tissue engineering bioreactors to gain mechanistic insights due to affordability, 
flexibility and precision (Godara et al., 2008). Mesenchymal stem cells proliferation, motility 
and osteogenic differentiation in response to various culture regimes was studied using 
time-lapse imaging of 96 culture chambers within a single microfluidic chip (lab-on-a-chip) 
(Gomez-Sjoberg et al., 2007). However, one of the challenges is absorption of small 
hydrophobic molecules, typically hormones, by the plastic used for producing the 
microchips (Gomez-Sjoberg et al., 2010). Such methods may lend themselves well to 
studying the issue of MSC population heterogeneity, incomplete MSC chondrogenic 
programming, evaluation of novel chondrogenic inducing small molecules and signaling 
pathways involved in chondrogenic differentiation as identified elsewhere (Huang et al., 
2010c). A potential limitation of such micro-bioreactors is that they mainly evaluate 2D 
structures and cartilage tissue tends to prefer a 3D environment.  
As outlined, sophisticated bioreactors are currently available in a few labs for the generation 
and real-time analysis of cartilage constructs. However, the mechanical properties of the 
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produced cartilage remain significantly inferior to that of native cartilage although 
histological, biochemical and gene expression assays may indicate otherwise. A major 
drawback of most publications to date is the omission of a relevant positive biological 
control sample such as native cartilage. Most studies compare the test sample to a negative 
control sample consisting of the empty cell scaffold/carrier. Such study designs make it 
difficult to determine the biological relevance/utility of the engineered tissue. This being 
said, it is probably unknown when an engineered tissue is “good enough” for clinical 
implantation. This will likely depend on the constructs used as well as the patient age, lesion 
location and severity, and the accompanying rehabilitation program. Mature native tissue of 
the tissue of interest is likely the best biological yardstick presently, but the degree of tissue 
maturation preferable at the time of transplantation remains undetermined.  
As alluded to already, another major challenge is the development of aseptic, cost effective, 
bioreactor systems that will fulfill current regulatory requirements. A significant segment of 
the bioreactor industry is dedicated to the development of disposable systems as reviewed 
elsewhere (D'Aquino, 2006; Eibl and Eibl, 2009; Singh, 1999). These systems include wave-
mixed, orbital shaken and stirred bioreactors (Eibl et al., 2010). These systems may provide 
cost-effective solutions due to savings on operative utility, cleaning and validation costs as 
well as reduced water and cleaning agent consumption for cleaning. Some of the challenges 
are real-time analysis of the process due to range limitations of disposable sensors, pre-
validation that would shift the regulatory burden from the end-user to the manufacturer, 
incompatibilities with certain chemicals and temperatures, and limited accessories such as 
valves and sampling systems (Eibl et al., 2010; D'Aquino, 2006). These systems have not yet 
been significantly evaluated for cartilage engineering.  
De novo tissue engineering has also been investigated, where the so-called cell niche is 
relied upon to direct transplanted cells or tissue pieces towards the appropriate tissue has 
also been investigated (Grad et al., 2011; Shah et al., 2010; Stevens et al., 2005). This approach 
is often autologous in nature and associated with minimal handling and laboratory 
exposure of the cells. ACI and MACI are examples of this strategy. However, the resulting 
repair tissue remains inferior to native cartilage. Recently, self-assembling nanofibers were 
shown to promote cartilage repair of full thickness chondral defects in rabbits (Shah et al., 
2010). Alternatively, tissue can be made in vivo at a site distant to the ultimate repair site for 
later relocation to the injury site. Such de novo tissue formation was elegantly demonstrated 
for bone regeneration in a rabbit model (Stevens et al., 2005). Bone formation was induced 
by alginate injection under the tibial periosteum and later the neo-bone was removed and 
transplanted into an induced cortical bone defect where it promoted bone healing. Cartilage 
tissue was also generated using this model by adding molecules to the gel that inhibited 
angiogenesis and promoted chondrogenesis.  
The influence of oxygen tension during cell and tissue culture has also been investigated in 
relation to cartilage engineering and is an area, which appears to deserve further 
investigation. Low oxygen levels have been reported to be a more potent promoter of 
chondrogenesis than dynamic compression (Meyer et al., 2010). Previous studies have 
shown controversial findings in relation to the effect of oxygen tension on chondrogenic 
differentiation of mesenchymal stem cells with some reporting increased proliferation rates 
and chondrogenic potency and others reporting reduced proliferation and differentiation 
potency (Grayson et al., 2007; Merceron et al., 2010; Krinner et al., 2009; Holzwarth et al., 
2010). 
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6. Pre-clinical animal models for safety and efficacy evaluation of engineered 
cartilage 
Cartilage defects are “quality-of-life” lesions, as opposed to life-threatening conditions, for 
which therapies are available today that provide palliative relief for a large number of 
patients. Since long-term safety of new cell-based treatment modalities have yet to be 
determined it is possible that adverse effects could ultimately lead to worse quality of life 
than the initial cartilage problem caused. Thorough evaluation of efficacy and long-term 
safety is therefore prudent before introducing new cell-based therapies for such lesions. In 
vivo studies can generally be categorized into models where the animal is used as the 
bioreactor directly at the injury site or at a distant site for later relocation to the injury site, as 
discussed above, or as models were animals are used to evaluate in vitro engineered 
constructs. 
Members of the Orthopaedic Trauma Association (OTA) recently discussed pre-clinical 
animal models for cartilage and bone repair (Lansdowne, 2010; Martineau, 2010). This topic 
has also been reviewed by a number of authors (Pearce et al., 2007; Reinholz et al., 2004; Chu 
et al., 2010; Koch and Betts, 2007). The consensus with regard to cartilage defects is that the 
research question determines the choice of model, since there is no ideal pre-clinical animal 
model. General issues to consider are the lesion model (chondral, osteochondral, 
degenerative), most appropriate model (cost, availability, joint structure, age), cartilage 
similarity (thickness, structure, cell density, biochemistry, biomechanics), and the nature of 
the lesion (area, depth, location) (Martineau, 2010). Small animal models are rodents and 
rabbits. Rodent models have limited translational value, but are cost effective models for 
mechanistic studies of chondrogenesis, generation of proof-of-concept data and bridging in 
vitro and large animal studies. Rabbits are easy to handle and cost effective, but have thin 
cartilage with excellent endogenous repair potential as well as highly flexible joints which 
support a relatively low body weight (low loading of the joints). Large animal models 
include minipigs, goats, and horses (Martineau, 2010). Mini-pigs do not comply with 
rehabilitation programs, but advantages comprise joint size sufficiently large to allow 
arthroscopy, partial or full-thickness chondral defects, growth plate closure, poor 
endogenous chondral repair potential and the possibility of making 6-8 mm diameter size 
lesions. Goats (as well as sheep) are similar to mini-pigs in that they do not comply with 
rehabilitation programs, but allow arthroscopic approaches and large defects can be made in 
cartilage that have limited intrinsic repair potential. Goats and sheep studies are more 
expensive due to increased housing and handling costs. Horses can comply with 
rehabilitation programs, allow for defect sizes similar to human defects, exert low intrinsic 
repair potential and arthroscopic treatment modalities and make follow-up assessment 
possible. The drawback of equine studies is high cost, high loading forces, and hard bone, 
and it is difficult to achieve protected weight bearing in the horse. 
The OTA study group on bone defect models had the following universal considerations: 
consider the 3R’s of animal use and reduce, refine and replace before choosing the most 
relevant animal model; perform a pilot study if inexperienced with the model; animal 
models do not account for co-morbidities (e.g. obesity, diabetes etc); ensure optimal animal 
care before and after surgery by consulting with veterinary specialists in surgery 
(www.acvs.org or www.ecvs.org), anesthesia (www.acva.org or www.ecva.eu.org), and 
laboratory animal medicine (www.aclam.org or www.eclam.org); ideally standardize your 
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model with a negative and a positive control although in comparative studies comparison 
with the current “golden standard” treatment is sufficient (Lansdowne, 2010).  
The argument for increased use of domestic animal species as pre-clinical animal models is 
based on the fact that many human conditions have a spontaneous counter-part in animals 
that would allow for more physiologically relevant studies compared to induced lesions in 
inbreed subpopulations of small laboratory animals. Veterinary medicine today often rivals 
human medicine with regard to diagnostic and treatment modalities, some companion 
animals largely live in the same epigenetic environment as humans, and the veterinary 
market is of significant monetary value in itself (Koch et al., 2009; Koch and Betts, 2007). 
Most recently, induced pluripotent stem cells (iPS cells) have been generated from equine 
cells for the purpose of treating sporting horses as well as utilizing the horse as a pre-clinical 
animal model of comparative human disorders (Nagy et al., 2011). Stem cells and animal 
therapies have recently been reviewed elsewhere (Figueroa et al., 2011).  The sentiment from 
2004 by Fiester and colleagues that successful treatment of a spontaneous animal disorder 
may significantly advance stem cell research remains valid today and could be expanded to 
include the field of regenerative medicine (Fiester et al., 2004).  
7. Conclusion and future perspectives 
The field of cartilage tissue engineering is a very diverse research field investigating the use 
of bioreactors, scaffold compositions and designs in combination with a wide range of cells 
and cytokines. It is still an emerging research field and careful pre-clinical assessment of the 
potential treatment modalities is advised to avoid long-term adverse effects (Figure 5). 
However, these treatment modalities hold the potential of providing life-long solutions to 
the currently incurable problem of joint cartilage damage. Domestic animal models may 
provide valuable translation significance between proof-of-principle studies in small 
laboratory animals and expensive human pre-clinical trials. 
 
 
Fig. 5. Clinical roadmap for bone tissue engineering bioreactors. This roadmap is equally 
useful for cartilage engineering. In vivo proof-of-principle can be shown in laboratory 
animal models, but domestic animal models may be of more translation value prior to 
human clinical trials. Reprinted with permission from Yeatts and Fisher (2011)  
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Text Box 1. Selected physical outcome parameters used in cartilage engineering 
Stress, strain and frequency are often referred to in tissue engineering so a brief 
description of these terms is warranted. Stress, often denoted as sigma (ǔ), is the amount 
of force acting over a given cross-sectional area. Stress is expressed as force per area units. 
The unit of stress is pascal (Pa) or newtons (N) per area in the metric system, and psi in 
the English system. Conversions of these different units are as follows: 1 psi = lbF/in2, 1 
Pa = 1.45 x 10-4 psi, 1 Pa = 1 N/m2, 1 kPa = 1 where Newton (N) is the SI unit of force. 1 N 
= kg m/s2, e.g. the net force required to accelerate a mass of one kilogram at a rate of one 
meter per second squared. Engineering strain, often denoted as ε, is the nominal change 
in length of a material (ε = ∆L/L0 = (L – L0)/L0). The unit of strain is often mm/mm, 
cm/cm, etc, or no unit at all since it is the ratio of a given measuring system. Frequency, 
denoted with the SI unit hertz (Hz), is the number of cycles per second, typically of a sine 
wave. Shear stress, Ǖ, as exerted on cells in perfusion systems with a laminar flow profile 
between the ingress and egress plates can be calculated as follows: Ǖ = (6μQ)/(bh2), where 
μ is the viscosity of the medium, Q is the volumetric flow rate, b is the width of flow 
channel, and h is the distance between the two plates (Shiragami and Unno, 1994; Nagel-
Heyer et al., 2005). The shear stress unit is force per area, e.g. N/m2 or similar 
representation of force per area using psi, Pa and in2 or cm2. Other physical parameters 
often used in cartilage engineering such as Darcy’s law, Reynolds number (Re), mass flow 
rate, flow velocity has been reviewed elsewhere (Concaro et al., 2009). 
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